Product image of Iretig (Mirabegron) supplied by GNH India

Iretig

Active Ingredient:
Mirabegron
Origin:
EU

Iretig (Mirabegron)

Mirabegron, the active ingredient in Iretig, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the management of overactive bladder symptoms such as urgency, frequency, and urge incontinence in adults.

GNH India supplies Iretig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegron acts on the β3‑adrenergic pathway to improve bladder storage function.

  • Overactive bladder: increases bladder capacity and reduces episodes of urgency.
  • Urinary urgency: lessens the sudden need to void.
  • Urinary frequency: decreases the number of daily voids.

How It Works

  • Mirabegron selectively stimulates β3‑adrenergic receptors in the detrusor smooth muscle of the bladder. Activation of these receptors leads to relaxation of the detrusor during the storage phase, thereby increasing functional bladder capacity and reducing involuntary contractions that cause urgency and frequency.

Side Effects

Adverse reactions may occur with mirabegron therapy.

Common Side Effects

  • Hypertension: elevated blood pressure readings.
  • Nasopharyngitis: mild upper respiratory tract infection.
  • Headache: transient cranial pain.
  • Dry mouth: reduced salivary flow.
  • Constipation: decreased bowel movements.
  • Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

  • Urinary retention: difficulty initiating or maintaining urine flow.
  • Severe hypertension: markedly high blood pressure requiring medical attention.
  • Cardiac arrhythmias: irregular heart rhythms observed in rare cases.
  • Angioedema: swelling of face, lips, or throat.
  • Severe allergic reaction: rash, itching, or anaphylaxis.
  • Liver enzyme elevation: abnormal hepatic function tests.

Precautions & Warnings

Patients should be aware of specific safety considerations before starting mirabegron.

  • Blood pressure monitoring: check baseline and periodic readings.
  • Cardiovascular disease: assess risk before use.
  • Drug interactions: review concomitant medications for potential effects on blood pressure.
  • Renal impairment: adjust therapy based on kidney function.
  • Pregnancy and lactation: avoid use unless benefits outweigh risks.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Mirabegron may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

  • CYP2D6 substrates (e.g., metoprolol): may increase plasma levels.
  • Antihypertensives (e.g., ACE inhibitors): additive blood pressure effects.

Moderate Interactions (Monitor Closely)

  • Anticholinergics (e.g., oxybutynin): may reduce efficacy of mirabegron.
  • Diuretics: potential for altered fluid balance.
  • NSAIDs: increased risk of hypertension.
  • Digoxin: possible increase in serum concentration.
  • CYP3A4 inhibitors (e.g., ketoconazole): may raise mirabegron exposure.

Frequently Asked Questions

Iretig, containing mirabegron, is prescribed for adults with overactive bladder symptoms, including urinary urgency, increased frequency, and urge incontinence. It helps improve bladder storage capacity and reduces the need for frequent bathroom trips.

Mirabegron selectively activates β3‑adrenergic receptors in the bladder’s detrusor muscle. This activation relaxes the muscle during the filling phase, allowing the bladder to hold more urine and decreasing involuntary contractions that cause urgency and frequency.

The appropriate dose of Iretig is determined by the prescribing healthcare professional based on the patient’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of mirabegron in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Iretig product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Iretig (mirabegron) belongs to a different class—β3‑adrenergic agonists—while antimuscarinics block muscarinic receptors. Mirabegron often has a lower incidence of dry mouth and constipation, common side effects of antimuscarinics, but may raise blood pressure, requiring monitoring.

Iretig tablets should be stored at ambient temperature, below 25 °C. Keep them in the original container, protect from moisture, and store out of direct sunlight to maintain product stability.

Iretig is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include significant hypertension, urinary retention, and rare cardiac arrhythmias. Patients experiencing a sudden increase in blood pressure, difficulty urinating, or irregular heartbeats should seek medical attention promptly.

Iretig is contraindicated in patients with uncontrolled hypertension, severe urinary retention, or known hypersensitivity to mirabegron. Caution is also advised for individuals with significant cardiovascular disease, renal impairment, or those taking strong CYP2D6 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT